Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 369

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 369
---
 B7 (p=0.043), B9 (p=0.001), B12 (p=0.001). Additionally, levels of lipopolysaccharides (p=0.015), which play a role in immune function, were lower compared to the healthy reference group in our database. These differences were clear, consistent, and statistically significant. Based on these findings, we provided personalized nutrition recommendations to help participants improve their health datapoints. For example, when someone had less diverse gut bacteria and lower short -chainfatty acids production, we suggested a tailored diet. This included adding more fermented foods (like yogurt), seeds, and whole -graincereals. These foods contain prebiotic fiber and arabinoxylans — nutrients that nourish the gut bacteria responsible for producing short -chainfatty acids. Short -chainfatty acids help reduce inflammation and strengthen the immune system, leading to better overall health. For the construction of gut microbiome references databases in other countries or regions, participant selection, sample collection, and analysis are being conducted following the same methodology used for the Argentinian database. In Mexico, we have collected 80 biological samples to date from Mexico City. The collection was carried out in coordination with a local laboratory, to which we provided payment for the sample collection. In each new country where we plan to launch Rewell, the same sample collection process will be carried out in conjunction with local entities as we do not rely on existing reference datasets. Personal DNA and Gut Microbiome Profiling Rewell provides customers with direct access to their DNA and gut microbiome information, enabling more informed long -termhealth decisions aimed at minimizing the risk of chronic disease development. This includes insights into genetic ancestry origins and personal genetic health risks, presented through Polygenic Risk Scores (“PRS”), which provides a measure of disease risk based on genetic factors. Rewell also delivers insights on dietary intolerances, physical activity and rest optimization, and specific nutrient impact on gene function and longevity. For PRS reporting, we apply scores from the PGS Catalog, an open database of polygenic scores (PGS), calculated using low -passgenome (“LPG”) sequencing followed by genotype imputation. LPG technology is a high -throughputsolution that produces low coverage of a whole human genome. Samples are sequenced with Illumina technology at a depth of 1X, generating approximately 3 GB of data per sample and a total of 20million reads per sample. For 183 reference, complete genome